273 related articles for article (PubMed ID: 12746781)
1. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study.
Vibhagool A; Sungkanuparph S; Mootsikapun P; Chetchotisakd P; Tansuphaswaswadikul S; Bowonwatanuwong C; Ingsathit A
Clin Infect Dis; 2003 May; 36(10):1329-31. PubMed ID: 12746781
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial.
Miro JM; Lopez JC; Podzamczer D; Peña JM; Alberdi JC; Martínez E; Domingo P; Cosin J; Claramonte X; Arribas JR; Santín M; Ribera E;
Clin Infect Dis; 2006 Jul; 43(1):79-89. PubMed ID: 16758422
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study.
Mussini C; Pezzotti P; Miró JM; Martinez E; de Quiros JC; Cinque P; Borghi V; Bedini A; Domingo P; Cahn P; Bossi P; de Luca A; d'Arminio Monforte A; Nelson M; Nwokolo N; Helou S; Negroni R; Jacchetti G; Antinori S; Lazzarin A; Cossarizza A; Esposito R; Antinori A; Aberg JA;
Clin Infect Dis; 2004 Feb; 38(4):565-71. PubMed ID: 14765351
[TBL] [Abstract][Full Text] [Related]
5. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
[TBL] [Abstract][Full Text] [Related]
7. Cryptococcal meningitis in HIV-infected patients: a longitudinal study in Cambodia.
Espié E; Pinoges L; Balkan S; Chanchhaya N; Molfino L; Narom P; Pujades-Rodríguez M
Trop Med Int Health; 2010 Nov; 15(11):1375-81. PubMed ID: 20868415
[TBL] [Abstract][Full Text] [Related]
8. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
[TBL] [Abstract][Full Text] [Related]
9. Hearing loss after discontinuing secondary prophylaxis for cryptococcal meningitis: relapse or immune reconstitution?
Khanna N; Nüesch R; Buitrago-Tellez C; Battegay M; Hirsch HH
Infection; 2006 Jun; 34(3):163-8. PubMed ID: 16804661
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
[TBL] [Abstract][Full Text] [Related]
11. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
12. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
13. Interruption of prophylaxis for major opportunistic infections in HIV-infected patients receiving triple combination antiretroviral therapy.
Jubault V; Pacanowski J; Rabian C; Viard JP
Ann Med Interne (Paris); 2000 May; 151(3):163-8. PubMed ID: 10896967
[TBL] [Abstract][Full Text] [Related]
14. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy.
Goldman M; Zackin R; Fichtenbaum CJ; Skiest DJ; Koletar SL; Hafner R; Wheat LJ; Nyangweso PM; Yiannoutsos CT; Schnizlein-Bick CT; Owens S; Aberg JA;
Clin Infect Dis; 2004 May; 38(10):1485-9. PubMed ID: 15156489
[TBL] [Abstract][Full Text] [Related]
15. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.
ter Horst R; Collin SM; Ritmeijer K; Bogale A; Davidson RN
Clin Infect Dis; 2008 Jun; 46(11):1702-9. PubMed ID: 18419422
[TBL] [Abstract][Full Text] [Related]
16. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
[TBL] [Abstract][Full Text] [Related]
17. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
19. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia.
Madec Y; Laureillard D; Pinoges L; Fernandez M; Prak N; Ngeth C; Moeung S; Song S; Balkan S; Ferradini L; Quillet C; Fontanet A
AIDS; 2007 Jan; 21(3):351-9. PubMed ID: 17255742
[TBL] [Abstract][Full Text] [Related]
20. Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature.
Skiest DJ; Hester LJ; Hardy RD
J Infect; 2005 Dec; 51(5):e289-97. PubMed ID: 16321643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
